Needham Reiterates Buy on NeoGenomics, Maintains $21 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Mike Matson has reiterated a 'Buy' rating on NeoGenomics (NASDAQ:NEO) and maintained a price target of $21.
August 09, 2023 | 8:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a 'Buy' rating on NeoGenomics, maintaining a price target of $21. This could potentially boost investor confidence in the stock.
Analyst ratings often influence investor sentiment. A reiterated 'Buy' rating indicates that the analyst continues to have confidence in the company's performance. This could potentially lead to increased investor interest and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100